| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.CLPT.2005.08.018 |
| P698 | PubMed publication ID | 16338279 |
| P50 | author | Michael Hutchinson | Q43496348 |
| Koen Vandenbroeck | Q59976200 | ||
| P2093 | author name string | Chris Patterson | |
| Colin Graham | |||
| Stanley Hawkins | |||
| Gavin McDonnell | |||
| Stephen Cunningham | |||
| Aidan Droogan | |||
| Killian O'Rourke | |||
| P2860 | cites work | Ensembl 2005 | Q24797999 |
| P433 | issue | 6 | |
| P921 | main subject | pharmacogenomics | Q1152227 |
| P304 | page(s) | 635-646 | |
| P577 | publication date | 2005-12-01 | |
| P1433 | published in | Clinical Pharmacology & Therapeutics | Q1101529 |
| P1476 | title | Pharmacogenomics of responsiveness to interferon IFN-beta treatment in multiple sclerosis: a genetic screen of 100 type I interferon-inducible genes | |
| P478 | volume | 78 |
| Q42968396 | A critical function of toll-like receptor-3 in the induction of anti-human immunodeficiency virus activities in macrophages |
| Q36059972 | An integrated approach to design novel therapeutic interventions for demyelinating disorders |
| Q34712125 | Candidate gene study of TRAIL and TRAIL receptors: association with response to interferon beta therapy in multiple sclerosis patients |
| Q37294866 | Cathepsins and their endogenous inhibitors cystatins: expression and modulation in multiple sclerosis |
| Q37484571 | Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis |
| Q37848651 | Determinants of interferon β efficacy in patients with multiple sclerosis |
| Q37793151 | Differential Gene Expression and Translational Approaches to Identify Biomarkers of Interferon Beta Activity in Multiple Sclerosis |
| Q36001691 | Endogenous, or therapeutically induced, type I interferon responses differentially modulate Th1/Th17-mediated autoimmunity in the CNS. |
| Q37307906 | Genetic polymorphisms, their allele combinations and IFN-beta treatment response in Irish multiple sclerosis patients |
| Q34016246 | Impairment of immunoproteasome function by β5i/LMP7 subunit deficiency results in severe enterovirus myocarditis |
| Q52332793 | Inflammasome Proteins As Biomarkers of Multiple Sclerosis. |
| Q35148010 | MxA mRNA quantification and disability progression in interferon beta-treated multiple sclerosis patients |
| Q51068027 | Myxovirus resistance protein A (MxA) polymorphism is associated with IFNβ response in Iranian multiple sclerosis patients. |
| Q39195523 | NSs protein of rift valley fever virus induces the specific degradation of the double-stranded RNA-dependent protein kinase |
| Q40072967 | Nipah and Hendra Virus Nucleoproteins Inhibit Nuclear Accumulation of Signal Transducer and Activator of Transcription 1 (STAT1) and STAT2 by Interfering with Their Complex Formation |
| Q38643129 | Pharmacogenetic Biomarkers to Predict Treatment Response in Multiple Sclerosis: Current and Future Perspectives. |
| Q64100676 | Pharmacogenomics of Multiple Sclerosis: A Systematic Review |
| Q37606292 | Predicting responders to therapies for multiple sclerosis |
| Q83429975 | Should we measure the bioavailability of interferon beta in vivo in patients with multiple sclerosis? |
| Q37990779 | Single nucleotide polymorphisms in multiple sclerosis: disease susceptibility and treatment response biomarkers. |
Search more.